

Supplementary Methods

The methods for the cultivation of differentiation of MSCs.

The fourth-passage MSCs were cultured in 24-well plates at a density of 1×10^4 cells per well. When the cells reached 50% to 70% confluence, the medium was replaced with adipogenic and osteogenic media (Gibco, USA) to induce adipogenic and osteogenic differentiation, respectively. Following a 21-day period, the cellular samples were preserved in a 4% formaldehyde solution and subsequently subjected to staining procedures utilizing Oil Red O (Sigma-Aldrich, USA) or Alizarin Red S (Sigma-Aldrich, USA), facilitating the evaluation of their respective adipogenic and osteogenic differentiation capacities.

To induce chondrogenesis, 2×10^5 cells from the fourth generation were subjected to centrifugation at 1200 rpm for 5 minutes, followed by the removal of the supernatant. Subsequently, chondrogenic induction medium (Gibco, USA) was introduced to assess the chondrogenic potential of HUCMSCs. Post a 21-day induction period, the cell pellets were fixed using a 4% formaldehyde solution, dehydrated via graded ethanol series, and embedded in an optimal cutting temperature (OCT) compound. The embedded samples were sectioned at a thickness of 5 mm and stained with Alcian Blue (Sigma-Aldrich, USA) to visualize the chondrogenic differentiation.

The ELISA kit.

Protein	Reactivity	Brand name	Detection limits
IL-6	Human	Jianglai biology (JL14113)	3.12-200pg/mL
MUC5AC	Human	Jiangsu Meimian Industirial Co., Ltd (MM-51046H1)	1-64ng/ml
CCL-20	Human	ABclonal (RK00207)	7.8-500pg/ml
IL-23	Human	Jianglai biology (JL119269)	1.56-100pg/mL
IL-17A	Human	Jiangsu Meimian Industirial Co., Ltd (MM-2117H1)	0.1-32pg/mL

Supplementary Figures

Figure S1





Figure S1: Identification of MSCs and the preservation of their viability in MSC eye drops.

(A) The schematic diagram for the production and transportation of MSC eye drops. (B) The identification of MSCs. MSCs negatively expressed CD14, CD19, CD34, CD45, and HLA-DR but positively expressed CD73, CD90, and CD105 by flow cytometry analysis. (C) The image of cell morphology displayed the adhesion of MSCs to the culture surface. (D) Oil red O staining, Alizarin Red S staining and Alcian Blue staining showed MSCs were induced into adipogenic, osteogenic, and chondrogenic cells respectively. (E) The representative images of Trypan blue staining at various time points on the MSC eye drops (the green circle indicates living cells and the red circle signifies dead cells). (F) The quantification of cell survival rate.

Abbreviations: GMP = Good Manufacturing Practice, MSCs=Mesenchymal Stem Cells.


Figure S2

A



B

NSDE



C

SSDE




Figure S2: (A)The PCA score plots for NSDE and SSDE groups. Significantly enriched GOCC and GOMF ($p < 0.05$) for (B) NSDE and (C) SSDE groups.

Abbreviations: PCA=Principal Component Analysis, DED= Dry eye disease, NSDE=non-Sjögren's syndrome dry eye, SSDE=Sjögren's syndrome dry eye. GO=Gene ontology, CC=Cellular Component, MF=Molecular Function

Figure S3




Figure S3: Representative images of meibomian gland deletion in the NSDE and SSDE patient groups pre-treatment.

Abbreviations: NSDE=non-Sjögren's syndrome dry eye, SSDE=Sjögren's syndrome dry eye.

Table S1: The treatment history of subjects.

Patient ID	Sex	Age (y)	Duration of diagnosed DED (months)	Intractable symptoms	The impact of symptoms on life	Kinds of previous therapies	List of previous therapies*	Efficacy of previous therapies (Treatment more than three months)
NSDE001	F	43	18	Dryness, itchy	Severe	1	Artificial tears	Failure
NSDE002	M	20	10	Photosthesia	Severe	2	Artificial tears; meibomian gland thermal pulsation	Mild relief
NSDE003	F	30	20	Dryness, redness	Severe	2	Artificial tears; corticosteroids	Failure
NSDE004	M	66	88	Dryness, pain	Very severe	4	Artificial tears; non-steroidal anti-inflammatory drugs; meibomian gland thermal pulsation and expression; others	Failure
NSDE005	F	59	16	Vision blurred, itchy	Very severe	3	Artificial tears; corticosteroids; intense pulsed light therapy	Failure
NSDE006	F	51	25	Foreign body sensation	Severe	2	Artificial tears; others	Failure
NSDE007	F	69	21	Dryness, pain	Very severe	3	Artificial tears; non-steroidal anti-inflammatory drugs; others	Failure
NSDE008	F	35	45	Dryness, pain	Severe	4	Artificial tears; non-steroidal anti-inflammatory drugs; meibomian gland thermal pulsation; others	Failure
NSDE009	F	38	40	Dryness, redness	Severe	2	Artificial tears; corticosteroids	Failure
NSDE010	F	39	12	Vision blurred, itchy	Severe	3	Artificial tears; corticosteroids; meibomian gland thermal pulsation and expression	Failure
NSDE011	F	25	26	Redness, itchy	Severe	3	Artificial tears; non-steroidal anti-inflammatory drugs; intense pulsed light therapy	Mild relief
SSDE001	F	55	92	Dryness, vision blurred, foreign body sensation	Very severe	3	Artificial tears; corticosteroids; meibomian gland thermal pulsation and expression	Failure
SSDE002	F	37	57	Vision blurred, pain	Very severe	3	Artificial tears; meibomian gland thermal pulsation and expression; others	Failure
SSDE003	F	68	78	Dryness, vision blurred, foreign body sensation	Very severe	2	Artificial tears; corticosteroids	Failure
SSDE004	F	40	49	Redness, itchy	Very severe	4	Artificial tears; corticosteroids; intense pulsed light therapy; others	Failure
SSDE005	M	46	56	Dryness, redness	Severe	3	Artificial tears; non-steroidal anti-inflammatory drugs; others	Failure

* Pharmacological: artificial tears, topical corticosteroids and non-steroidal anti-inflammatory drugs; Nonpharmacological therapeutics: meibomian gland thermal pulsation and expression, intense pulsed light therapy; others: acupuncture, Chinese Medicine. **Abbreviations:** F, female; M, male; DED, Dry eye disease.

Table S2: The scale standards.

	Grade 1	Grade 2	Grade 3	Grade 4
TMH scale	High ($\geq 0.35\text{mm}$)	Normal (0.2-0.35mm)	Relatively low (0.15-0.2mm)	Low ($< 0.15\text{ mm}$)
NIBUT scale	High ($\geq 15\text{s}$)	Normal (11-15s)	Relatively low (7-11s)	Low ($< 7\text{s}$)
Lipid layer scale	Yellow–gray lipid layer	Red–blue lipid layer	Gray lipid layer	Light white lipid layer
Meibomian gland orifices scale	No block	A few blocked glands	Several blocked glands	A few opened glands
Meibomian gland deletion scale	No absence	$< 1/3$ of glands absent	$> 1/3$ but $< 2/3$ of glands absent	$> 2/3$ glands absent
Redness scale	No congestion at all	Mild congestion	Moderate congestion	Severe congestion

Abbreviations: TMH=tear meniscus height, NIBUT=non-invasive break-up time.

Table S3: The primary efficacy indicators assessment for long-term follow-up (F-month12) of NSDE and SSDE patients.

		NSDE		SSDE	
		Number of eyes (n=16)		Number of eyes (n=10)	
		Mean $\pm$ SEM	P value (F-month12 vs)	Mean $\pm$ SEM	P value (F-month12 vs)
OSDI score	Baseline	40.67 $\pm$ 8.425	0.0489 (*)	48.8 $\pm$ 8.303	0.164 (ns)
	T-week2	24.22 $\pm$ 7.015	>0.9999 (ns)	21 $\pm$ 4.68	>0.9999 (ns)
	F-month12	23.25 $\pm$ 6.678		22.6 $\pm$ 5.354	
TMH (mm)	Baseline	0.1606 $\pm$ 0.00769	0.0003 (***)	0.214 $\pm$ 0.02187	0.7929 (ns)
	T-week2	0.2839 $\pm$ 0.01106	0.1041 (ns)	0.286 $\pm$ 0.01939	0.0032 (**)
	F-month12	0.2413 $\pm$ 0.01791		0.205 $\pm$ 0.01344	
First NIBUT (s)	Baseline	5.469 $\pm$ 0.5746	0.0149 (*)	5.647 $\pm$ 1.443	0.6444 (ns)
	T-week2	9.324 $\pm$ 1.25	0.7941 (ns)	7.751 $\pm$ 1.669	0.1266 (ns)
	F-month12	8.55 $\pm$ 1.142		4.48 $\pm$ 0.7123	
Average NIBUT (s)	Baseline	7.708 $\pm$ 0.6882	0.0002 (***)	8 $\pm$ 1.464	0.7272 (ns)
	T-week2	12.13 $\pm$ 0.9216	0.4382 (ns)	10.63 $\pm$ 1.516	0.1018 (ns)
	F-month12	11.32 $\pm$ 1.075		6.928 $\pm$ 0.9608	
SIT (mm/5 min)	Baseline	4.111 $\pm$ 0.808	0.0038 (**)	2.5 $\pm$ 0.6708	0.3706 (ns)
	T-week2	17.5 $\pm$ 2.399	0.0071 (**)	8 $\pm$ 0.9661	0.5976 (ns)
	F-month12	12.94 $\pm$ 2.351		5.8 $\pm$ 2.318	
CFS score	Baseline	1.111 $\pm$ 0.3951	0.4318 (ns)	3.1 $\pm$ 0.9939	>0.9999 (ns)
	T-week2	0.1111 $\pm$ 0.1111	>0.9999 (ns)	1.8 $\pm$ 0.6799	0.6286 (ns)
	F-month12	0.3125 $\pm$ 0.1983		2.1 $\pm$ 0.8876	
		n, (%)	P value (F-month12 vs)	n, (%)	P value (F-month12 vs)

TMH scale	Baseline	Grade 1	0 (0)	0.0094(**)	0 (0)	0.8677(ns)
		Grade 2	1 (4.6)		3 (30.0)	
		Grade 3	12 (54.5)		6 (60.0)	
		Grade 4	9 (40.9)		1 (10.0)	
	T-week2	Grade 1	2 (10)	0.4382(ns)	2 (20)	0.0673(ns)
		Grade 2	18 (90)		8 (80.0)	
		Grade 3	0 (0)		0 (0)	
		Grade 4	0 (0)		0 (0)	
	F- month12	Grade 1	1 (6.2)		0 (0)	
		Grade 2	10 (62.5)		6 (60.0)	
		Grade 3	5 (31.2)		3 (30.0)	
		Grade 4	0(0)		1 (10.0)	
NIBUT scale	Baseline	Grade 1	0 (0)	0.0267(*)	2 (20.0)	>0.9999(ns)
		Grade 2	3 (13.6)		0 (0)	
		Grade 3	11 (50)		3 (30.0)	
		Grade 4	8 (36.4)		5 (50.0)	
	T-week2	Grade 1	5 (25.0)	0.7535(ns)	2 (20.0)	0.235(ns)
		Grade 2	6 (30.0)		2 (20.0)	
		Grade 3	8 (40.0)		4 (40.0)	
		Grade 4	1 (5.0)		2 (20.0)	
	F- month12	Grade 1	4 (25.0)		0 (0)	
		Grade 2	3 (18.8)		1 (10.0)	
		Grade 3	7 (43.8)		3 (30.0)	
		Grade 4	2 (12.5)		6 (60.0)	

Abbreviations: NSDE=non-Sjögren's syndrome dry eye, SSDE=Sjögren's syndrome dry eye, OSDI= Ocular Surface Disease Index, TMH=tear meniscus height, NIBUT=non-invasive break-up time, SIT=Schirmer I test, CFS=corneal fluorescein stain. The Data of OSDI, TMH, First/average NIBUT, SIT and CFS score are presented as the Mean±SEM. The scaled data are presented as number (percentage). A *p*-value < 0.05 denoted statistical significance. The scale standards were shown in Table S2.

Table S4: The secondary efficacy indicators assessment for long-term follow-up (F-month12) of NSDE and SSDE patients.

			Number of eyes (n=16) NSDE		SSDE Number of eyes (n=10)	
			n, (%)	P value (F-month12 vs)	n, (%)	P value (F-month12 vs)
Lipid layer scale	Baseline	Grade 1	0 (0)	0.1269(ns)	0 (0)	0.8677(ns)
		Grade 2	4 (18.2)		4 (40.0)	
		Grade 3	9 (40.9)		4 (40.0)	
		Grade 4	9 (40.9)		2 (20.0)	
	T-week2	Grade 1	1 (5.0)	0.2232(ns)	0 (0)	0.5271(ns)
		Grade 2	17 (85.0)		8 (80.0)	
		Grade 3	2 (10.0)		2 (20.0)	
		Grade 4	0 (0)		0 (0)	
	F-month12	Grade 1	0 (0)		0 (0)	
		Grade 2	9 (56.2)		5 (50.0)	
		Grade 3	7 (43.8)		5 (50.0)	

Meibomian gland orifices scale	Baseline	Grade 4	0 (0)	0.1542(ns)	0 (0)	>0.9999(ns)
		Grade 1	0 (0)		0 (0)	
		Grade 2	7 (31.8)		4 (40.0)	
		Grade 3	12 (54.6)		6 (60.0)	
	T-week2	Grade 4	3 (13.6)	0.4318(ns)	0 (0)	0.0378(*)
		Grade 1	5 (25.0)		1 (10.0)	
		Grade 2	13 (65.0)		9 (90.0)	
		Grade 3	2 (10.0)		0 (0)	
	F-month12	Grade 4	0 (0)		0 (0)	
		Grade 1	0 (0)		0 (0)	
		Grade 2	12 (75.0)		4 (40.0)	
		Grade 3	4 (25.0)		6 (60.0)	
Meibomian gland deletion scale	Baseline	Grade 4	0 (0)	0.2232(ns)	0 (0)	0.1871(ns)
		Grade 1	2 (9.1)		0 (0)	
		Grade 2	8 (36.4)		6 (60.0)	
		Grade 3	11 (50)		3 (30.0)	
	T-week2	Grade 4	1 (4.5)	>0.9999(ns)	1 (10.0)	0.0146(*)
		Grade 1	3 (15.0)		0 (0)	
		Grade 2	8 (40.0)		8 (80.0)	
		Grade 3	9 (45.0)		2 (20.0)	
	F-month12	Grade 4	0 (0)		0 (0)	
		Grade 1	2 (12.5)		0 (0)	
		Grade 2	9 (56.2)		0 (0)	
		Grade 3	5 (31.2)		10 (100.0)	
Redness scale	Baseline	Grade 4	0 (0)	>0.9999ns	0 (0)	0.0883(ns)
		Grade 1	18 (81.8)		8 (80.0)	
		Grade 2	4 (18.2)		2 (20.0)	
		Grade 3	0 (0)		0 (0)	
	T-week2	Grade 4	0 (0)	>0.9999(ns)	0 (0)	0.0146(*)
		Grade 1	1 (5.0)		10 (100.0)	
		Grade 2	19 (95.0)		0 (0)	
		Grade 3	0 (0)		0 (0)	
	F-month12	Grade 4	0 (0)		0 (0)	
		Grade 1	13 (81.2)		2 (20.0)	
		Grade 2	3 (18.8)		8 (80.0)	
		Grade 3	0 (0)		0 (0)	
		Grade 4	0 (0)		0 (0)	

Abbreviations: NSDE=non-Sjögren's syndrome dry eye, SSDE=Sjögren's syndrome dry eye. The scaled data are presented as number (percentage). A *p*-value < 0.05 denoted statistical significance. The scale standards were shown in Table S2.

Supplementary File 1: The detail expression ratios of proteins in heatmaps.

NSDE:

Name	pre-treatment	post-treatment
MYL1	1	1.433985
MMP8	1	1.408697
H2AZ1	1	1.365175
NCF2	1	1.327561
PRTN3	1	1.214847
BPI	1	1.299028
MMP9	1	1.248383
MNDA	1	1.254645
SLC2A3	1	1.273922
NCF4	1	1.273739
ITGAM	1	1.252085
ELANE	1	1.176583
BASP1	1	1.197381
DEFA1	1	1.146796
H1-5	1	1.154762
ICAM3	1	1.204455
PSPH	1	1.227416
S100A2	1	1.148899
CYBB	1	1.186979
RETN	1	1.180636
NANP	1	1.170834
HK3	1	1.164536
ALOX5AP	1	1.136995
ITGB2	1	1.135038
VIM	1	1.119424
BPIFB1	1	1.150052
MPO	1	1.114132
CORO1A	1	1.103829
RAC2	1	1.11018
H1-2	1	1.124253
LCP1	1	1.08963
MARCKSL1	1	1.137927
LGALS1	1	1.114908
SSR3	1	1.1096
IGLV1-51	1	1.074014

SMPDL3A	1	1.108911
COX7A2	1	1.081779
H2BC12	1	1.074418
FSCN1	1	1.098321
CTSV	1	1.083865
FLNA	1	1.085116
NDUFA13	1	1.087837
CPM	1	1.095782
ANKRD28	1	0.808407
CNK3/IPCEF1	1	0.819327
MASP1	1	0.849652
INTS8	1	0.853198
ZFAND6	1	0.843769
NUP54	1	0.847549
PDRG1	1	0.855716
FHIP1A	1	0.880165
RBSN	1	0.882047
DVL2	1	0.901625

SSDE:

Name	pre-treatment	post-treatment
CRYAA	1	1.286353
REXO1L1P	1	1.480268
IGHE	1	1.278568
UBE2H	1	1.26495
BPIFB1	1	1.194761
SCGB1D2	1	1.149836
MFGE8	1	1.125863
ASPRV1	1	1.13165
A2M	1	1.093248
MUCL1	1	1.096536
DMBT1	1	1.083872
IL19	1	1.126394
AHCYL1	1	1.122735
DKK4	1	1.10678
UBE2O	1	1.137928
PELO	1	1.127771
ADGRV1	1	1.090064
TRIM26	1	1.116792
SERPINB12	1	1.105366
EIF2B3	1	1.115161
SERPINI1	1	1.095716

F10	1	1.107474
HPR	1	1.099839
SCGB1D1	1	1.062803
SCGB2A1	1	1.056618
SERPINA12	1	1.094426
LFNG	1	1.093332
CST4	1	1.057484
DCD	1	1.066072
S100A6	1	1.061107
MSLN	1	1.060711
APOF	1	1.090614
ST3GAL1	1	1.082594
OPRPN	1	1.054335
CXCL17	1	1.081299
FOLH1	1	1.076992
FN1	1	1.076146
PRR27	1	1.065586
HP	1	1.053746
SNRPN	1	1.094266
STK24	1	1.073154
S100A8	1	1.057229
VTN	1	1.061795
PON1	1	1.065457
OPA1	1	0.824052
CYP27A1	1	0.839414
SLIRP	1	0.835685
SIRPA	1	0.834672
MTMR1	1	0.860323
ABHD16A	1	0.861727
PGAM5	1	0.866129
ARHGAP25	1	0.861475
MIX23	1	0.870016
UQCRCQ	1	0.880191
TIMM8B	1	0.880016
C8orf82	1	0.887083
SFXN1	1	0.905984
HLA-DRB3	1	0.930256
ADGRE5	1	0.90635
NIPSNAP1	1	0.925033

Supplementary File 2: Parameters for the GO analysis.

NSDE:

Entry	Entry name	Entry class	Qe ratio	Bg ratio	Rich factor	Fold enrichment	P value	Count
GO:0098542	defense response to other organism	biological_process	12 52	319 4165	0.037617555	3.013021	0.000417	12
GO:0048870	cell motility	biological_process	10 52	273 4165	0.036630037	2.933925	0.001676	10
GO:0006955	immune response	biological_process	13 52	427 4165	0.030444965	2.438525	0.001733	13
GO:0030198	extracellular matrix organization	biological_process	5 52	72 4165	0.069444444	5.562233	0.001855	5
GO:0016043	cellular component organization	biological_process	12 52	400 4165	0.03	2.402885	0.003062	12
GO:0006897	endocytosis	biological_process	7 52	165 4165	0.042424242	3.398019	0.004005	7
GO:0002376	immune system process	biological_process	12 52	418 4165	0.028708134	2.299411	0.004409	12
GO:0022411	cellular component disassembly	biological_process	6 52	130 4165	0.046153846	3.696746	0.005162	6
GO:0000786	nucleosome	cellular_component	4 51	16 4315	0.25	21.15196	2.84E-05	4
GO:1990204	oxidoreductase complex	cellular_component	4 51	27 4315	0.148148148	12.5345	0.000249	4
GO:0005615	extracellular space	cellular_component	17 51	620 4315	0.027419355	2.319892	0.000475	17
GO:0005576	extracellular region	cellular_component	17 51	698 4315	0.024355301	2.060649	0.001881	17
GO:0043230	extracellular organelle	cellular_component	27 51	1411 4315	0.019135365	1.619002	0.002099	27
GO:0043226	organelle	cellular_component	27 51	1413 4315	0.01910828	1.61671	0.002148	27
GO:0031982	vesicle	cellular_component	27 51	1436 4315	0.018802228	1.590816	0.002796	27
GO:0004252	serine-type endopeptidase activity	molecular_function	6 47	70 3940	0.085714286	7.18541	0.000153	6
GO:0005198	structural molecule activity	molecular_function	7 47	125 3940	0.056	4.694468	0.000598	7
GO:0005178	integrin binding	molecular_function	4 47	63 3940	0.063492063	5.322526	0.00633	4
GO:0008233	peptidase activity	molecular_function	7 47	194 3940	0.036082474	3.024786	0.007402	7
GO:0003682	chromatin binding	molecular_function	4 47	77 3940	0.051948052	4.354794	0.012738	4
GO:0003677	DNA binding	molecular_function	7 47	234 3940	0.02991453	2.507729	0.019529	7
GO:0044877	protein-containing complex binding	molecular_function	8 47	328 3940	0.024390244	2.044629	0.03783	8

SSDE:

Entry	Entry name	Entry class	Qe ratio	Bg ratio	Rich factor	Fold	P value	Count
						enrichment		
GO:0007600	sensory perception	biological_process	5 52	64 3530	0.078125	5.303486	0.002255	5
GO:0007155	cell adhesion	biological_process	8 52	183 3530	0.043716	2.967633	0.004725	8
GO:0006954	inflammatory response	biological_process	6 52	122 3530	0.04918	3.338588	0.008348	6
GO:0030154	cell differentiation	biological_process	12 52	390 3530	0.030769	2.088757	0.00941	12
GO:0050789	regulation of biological process	biological_process	35 52	1946 3530	0.017986	1.220946	0.04934	35
GO:0006955	immune response	biological_process	10 52	383 3530	0.02611	1.772444	0.049436	10
GO:0005615	extracellular space	cellular_component	24 59	534 3651	0.044944	2.781185	7.94E-07	24
GO:0005576	extracellular region	cellular_component	19 59	615 3651	0.030894	1.911782	0.002648	19
GO:0031012	extracellular matrix	cellular_component	8 59	160 3651	0.05	3.094068	0.003758	8
GO:0030234	enzyme regulator activity	molecular_function	12 49	369 3352	0.03252	2.224656	0.005528	12
GO:0098772	molecular function regulator activity	molecular_function	11 49	412 3352	0.026699	1.826432	0.032023	11
GO:0005178	integrin binding	molecular_function	3 49	52 3352	0.057692	3.946625	0.039325	3

Supplementary File 3

NSDE-degree

ID	Name	Degree
P14780	MMP9	15
P05107	ITGB2	15
P11215	ITGAM	15
P05164	MPO	14
P15153	RAC2	11
P04839	CYBB	11
Q15080	NCF4	11
P08246	ELANE	10
Q9HD89	RETN	9
P22894	MMP8	9
P19878	NCF2	9
P20292	ALOX5AP	9
P13796	LCP1	8
P24158	PRTN3	7
P17213	BPI	7
P41218	MNDA	7
P08670	VIM	7
P31146	CORO1A	5
P52790	HK3	5
P59665	DEFA1	5
P0C0S5	H2AZ1	4
P16403	H1-2	4
P21333	FLNA	4
Q16658	FSCN1	4
P16401	H1-5	3
O60814	H2BC12	3
P32942	ICAM3	2
Q8TDL5	BPIFB1	2
P80723	BASP1	2
O14641	DVL2	1
P11169	SLC2A3	1
Q9NUG6	PDRG1	1
P09382	LGALS1	1
O60911	CTSV	1
P05976	MYL1	1
P14406	COX7A2	1
P49006	MARCKSL1	1

SSDE-degree

ID	Name	Degree
P01023	A2M	7
P02751	FN1	7
P04004	VTN	6
P00738	HP	6
P27169	PON1	5
P05109	S100A8	5
P01036	CST4	4
P00739	HPR	4
P00742	F10	4
O95969	SCGB1D2	3
O75556	SCGB2A1	3
Q08431	MFGE8	3
Q96DR8	MUCL1	3
Q9UGM3	DMBT1	3
O14949	UQCRQ	3
Q9Y5J9	TIMM8B	3
O95968	SCGB1D1	3
P06703	S100A6	2
Q13790	APOF	2
P81605	DCD	2
Q99935	OPRPN	2
Q13421	MSLN	2
P78324	SIRPA	2
Q9GZT3	SLIRP	2
Q04609	FOLH1	1
Q4VC31	MIX23	1
Q9H9B4	SFXN1	1
Q9C0C9	UBE2O	1
Q8IW75	SERPINA12	1
O60313	OPA1	1
Q11201	ST3GAL1	1
P62256	UBE2H	1
Q96P63	SERPINB12	1
Q96HS1	PGAM5	1